Link to this page
The Drug-Drug Interactions Ontology
| Preferred Name | canagliflozin | |
| Synonyms |
(1S)-1,5-anhydro-1-(3-{[5-(4-fluorophenyl)-2-thienyl]methyl}-4-methylphenyl)-D-glucitol C24H25FO5S (2S,3R,4R,5S,6R)-2-(3-{[5-(4-fluorophenyl)thiophen-2-yl]methyl}-4-methylphenyl)-6-(hydroxymethyl)oxane-3,4,5-triol 1-(Glucopyranosyl)-4-methyl-3-(5-(4-fluorophenyl)-2-thienylmethyl)benzene |
|
| ID |
http://purl.obolibrary.org/obo/CHEBI_73274 |
|
| AHFScode |
68:20.18
|
|
| ATCCode |
A10BX11
|
|
| binds |
http://purl.obolibrary.org/obo/dinto_1578 http://purl.obolibrary.org/obo/dinto_1583 http://purl.obolibrary.org/obo/dinto_1440 http://purl.obolibrary.org/obo/dinto_3582 http://purl.obolibrary.org/obo/dinto_0217 http://purl.obolibrary.org/obo/dinto_1850 http://purl.obolibrary.org/obo/dinto_0265 |
|
| CASRN |
842133-18-0
|
|
| DBBrand |
invokana
|
|
| DBSynonym |
canagliflozin hydrate
|
|
| Definition |
A C-glycosyl compound that is used (in its hemihydrate form) for treatment of type II diabetes via inhibition of sodium-glucose transport protein subtype 2. Canagliflozin belongs to a new class of anti-diabetic drugs that works by inhibiting the sodium-glucose transport protein (SGLT2). This transport protein is found in the kidney and is responsible for reabsorbing glucose that has been filtered. FDA approved on March 29, 2013.
|
|
| has pharmacological target | ||
| has role | ||
| InChI |
InChI=1S/C24H25FO5S/c1-13-2-3-15(24-23(29)22(28)21(27)19(12-26)30-24)10-16(13)11-18-8-9-20(31-18)14-4-6-17(25)7-5-14/h2-10,19,21-24,26-29H,11-12H2,1H3/t19-,21-,22+,23-,24+/m1/s1
|
|
| InChIKey |
InChIKey=XTNGUQKDFGDXSJ-ZXGKGEBGSA-N
|
|
| inhibits |
http://purl.obolibrary.org/obo/dinto_1578 |
|
| is metabolised by |
http://purl.obolibrary.org/obo/dinto_1850 |
|
| is substrate of |
http://purl.obolibrary.org/obo/dinto_3582 http://purl.obolibrary.org/obo/dinto_0217 http://purl.obolibrary.org/obo/dinto_1850 http://purl.obolibrary.org/obo/dinto_0265 http://purl.obolibrary.org/obo/dinto_0901 |
|
| is transported by | ||
| label |
canagliflozin
|
|
| may interact with |
http://purl.obolibrary.org/obo/CHEBI_4551 http://purl.obolibrary.org/obo/CHEBI_8107 http://purl.obolibrary.org/obo/CHEBI_8069 |
|
| prefixIRI |
obo2:CHEBI_73274
|
|
| prefLabel |
canagliflozin
|
|
| SMILES |
[H][C@]1(O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)c1ccc(C)c(Cc2ccc(s2)-c2ccc(F)cc2)c1 [H][C@]1(O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)C1=CC=C(C)C(CC2=CC=C(S2)C2=CC=C(F)C=C2)=C1
|
|
| Synonym |
(1S)-1,5-anhydro-1-(3-{[5-(4-fluorophenyl)-2-thienyl]methyl}-4-methylphenyl)-D-glucitol C24H25FO5S (2S,3R,4R,5S,6R)-2-(3-{[5-(4-fluorophenyl)thiophen-2-yl]methyl}-4-methylphenyl)-6-(hydroxymethyl)oxane-3,4,5-triol 1-(Glucopyranosyl)-4-methyl-3-(5-(4-fluorophenyl)-2-thienylmethyl)benzene
|
|
| xref |
RxList:http://www.rxlist.com/invokana-drug.htm Wikipedia:Canagliflozin CiteXplore:23564919 CiteXplore:23590413 ChEMBL:1451917 CiteXplore:22492586 CiteXplore:22548646 CiteXplore:22226086 National Drug Code Directory:50458-141-30 CiteXplore:22385274 Wikipedia:http://en.wikipedia.org/wiki/Canagliflozin Reaxys:18362681 CiteXplore:23087012 CiteXplore:23370138 Patent:WO2011142478 CiteXplore:23464594 CiteXplore:22621689 Patent:US2010099883 CiteXplore:21457428 CASRN:842133-18-0 CiteXplore:20690635 Patent:US2012289694 CiteXplore:23412078 ChEBI:73274 CiteXplore:22355316 Patent:WO2009035969 CiteXplore:23585665 CiteXplore:23279307 CiteXplore:22632452 Patent:US2008146515 CiteXplore:23563279 Drugs.com:http://www.drugs.com/invokana.html
|
|
| subClassOf |
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |